JP4999245B2 - 禁煙を達成するためのシステム - Google Patents
禁煙を達成するためのシステム Download PDFInfo
- Publication number
- JP4999245B2 JP4999245B2 JP2001510544A JP2001510544A JP4999245B2 JP 4999245 B2 JP4999245 B2 JP 4999245B2 JP 2001510544 A JP2001510544 A JP 2001510544A JP 2001510544 A JP2001510544 A JP 2001510544A JP 4999245 B2 JP4999245 B2 JP 4999245B2
- Authority
- JP
- Japan
- Prior art keywords
- nicotine
- containers
- formulation
- particles
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000391 smoking effect Effects 0.000 title claims description 38
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 248
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 244
- 229960002715 nicotine Drugs 0.000 claims description 244
- 239000002245 particle Substances 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 81
- 238000009472 formulation Methods 0.000 claims description 77
- 239000012528 membrane Substances 0.000 claims description 38
- 239000011148 porous material Substances 0.000 claims description 24
- 239000000843 powder Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 5
- 239000003380 propellant Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 230000009969 flowable effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims 8
- 238000000034 method Methods 0.000 description 44
- 210000004072 lung Anatomy 0.000 description 38
- 238000011282 treatment Methods 0.000 description 31
- 241000208125 Nicotiana Species 0.000 description 28
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 28
- 239000000443 aerosol Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 210000000621 bronchi Anatomy 0.000 description 9
- 230000002685 pulmonary effect Effects 0.000 description 9
- 230000036765 blood level Effects 0.000 description 8
- 229940071648 metered dose inhaler Drugs 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 235000019504 cigarettes Nutrition 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 230000005586 smoking cessation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 4
- UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 4
- 229950006073 cotinine Drugs 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000003123 bronchiole Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940112141 dry powder inhaler Drugs 0.000 description 3
- 238000005530 etching Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000002670 nicotine replacement therapy Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010057852 Nicotine dependence Diseases 0.000 description 2
- FXFANIORDKRCCA-UHFFFAOYSA-N Norcotinine Chemical compound N1C(=O)CCC1C1=CC=CN=C1 FXFANIORDKRCCA-UHFFFAOYSA-N 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- YHXKVHQFWVYXIC-JTQLQIEISA-N (S)-nicotine 1-N-oxide Chemical compound CN1CCC[C@H]1C1=CC=C[N+]([O-])=C1 YHXKVHQFWVYXIC-JTQLQIEISA-N 0.000 description 1
- MYKUKUCHPMASKF-VIFPVBQESA-N (S)-nornicotine Chemical compound C1CCN[C@@H]1C1=CC=CN=C1 MYKUKUCHPMASKF-VIFPVBQESA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- XOKCJXZZNAUIQN-IENPIDJESA-N 3-hydroxycotinine Chemical compound C1C(O)C(=O)N(C)[C@@H]1C1=CC=CN=C1 XOKCJXZZNAUIQN-IENPIDJESA-N 0.000 description 1
- BBNHNZGTKSWIHD-SNVBAGLBSA-N 5'-Hydroxycotinine Chemical compound CN1C(=O)CC[C@@]1(O)C1=CC=CN=C1 BBNHNZGTKSWIHD-SNVBAGLBSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MYKUKUCHPMASKF-UHFFFAOYSA-N Nornicotine Natural products C1CCNC1C1=CC=CN=C1 MYKUKUCHPMASKF-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- CIPULDKLIIVIER-VIFPVBQESA-N cotinine N-oxide Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN(=O)=C1 CIPULDKLIIVIER-VIFPVBQESA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
- A24F40/42—Cartridges or containers for inhalable precursors
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
- A24F40/10—Devices using liquid inhalable precursors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/06—Packaging for specific medical equipment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14414099P | 1999-07-16 | 1999-07-16 | |
| US60/144,140 | 1999-07-16 | ||
| PCT/US2000/019034 WO2001005459A1 (fr) | 1999-07-16 | 2000-07-12 | Systeme permettant d'arreter de fumer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003504165A JP2003504165A (ja) | 2003-02-04 |
| JP2003504165A5 JP2003504165A5 (fr) | 2007-09-13 |
| JP4999245B2 true JP4999245B2 (ja) | 2012-08-15 |
Family
ID=22507255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001510544A Expired - Fee Related JP4999245B2 (ja) | 1999-07-16 | 2000-07-12 | 禁煙を達成するためのシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20020179102A1 (fr) |
| EP (1) | EP1218048A4 (fr) |
| JP (1) | JP4999245B2 (fr) |
| AU (1) | AU777326B2 (fr) |
| CA (1) | CA2378913C (fr) |
| WO (1) | WO2001005459A1 (fr) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8256433B2 (en) | 1999-07-16 | 2012-09-04 | Aradigm Corporation | Systems and methods for effecting cessation of tobacco use |
| US6595210B2 (en) * | 2000-11-27 | 2003-07-22 | Unisia Jecs Corporation | Inhalator for administering powder composition |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
| WO2002094242A1 (fr) | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Administration de rizatriptan ou de zolmitriptan par voie d'inhalation |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| CA2446904A1 (fr) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Administration d'esters medicamenteux par inhalation |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| CA2447519C (fr) | 2001-05-24 | 2008-09-16 | Alexza Molecular Delivery Corporation | Administration par voie pulmonaire d'alprazolam, d'estazolam, de midazolam ou de triazolam |
| WO2003041693A1 (fr) | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Administration de diazepam a travers une voie pulmonaire |
| CA2460343A1 (fr) | 2001-11-21 | 2003-07-17 | Alexza Molecular Delivery Corporation | Delivrance de cafeine par voie inhalee |
| US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| CN100381083C (zh) | 2003-04-29 | 2008-04-16 | 韩力 | 一种非可燃性电子喷雾香烟 |
| JP2007516404A (ja) | 2003-05-21 | 2007-06-21 | アレックザ ファーマシューティカルズ， インコーポレイテッド | 光学点火されたかまたは電気点火された内蔵式加熱ユニットおよびそれを使用する薬剤供給ユニット |
| CN2719043Y (zh) | 2004-04-14 | 2005-08-24 | 韩力 | 雾化电子烟 |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| WO2006004646A1 (fr) * | 2004-06-28 | 2006-01-12 | Nektar Therapeutics | Formulation transformable en aerosol renfermant un sel de nicotine |
| FR2873584B1 (fr) * | 2004-08-02 | 2006-11-17 | Jean Jacques Hubinois | Systeme de sevrage tabagique |
| EP2246086A3 (fr) | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Dispositif d'administration de médicament en aérosol comprenant une unité de chauffage allumée par percussion |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達 |
| CN201067079Y (zh) | 2006-05-16 | 2008-06-04 | 韩力 | 仿真气溶胶吸入器 |
| EP2086527A4 (fr) * | 2006-12-01 | 2010-03-03 | Aradigm Corp | Systèmes destinés à mettre fin à l'usage du tabac |
| EP2121088B1 (fr) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Unité chauffante à utiliser dans un dispositif d'administration de médicament |
| CN201379072Y (zh) | 2009-02-11 | 2010-01-13 | 韩力 | 一种改进的雾化电子烟 |
| US20120048963A1 (en) | 2010-08-26 | 2012-03-01 | Alexza Pharmaceuticals, Inc. | Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter |
| EP2729148A4 (fr) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | Compositions et méthodes de traitement de symptômes chez des patients atteints de la maladie de parkinson |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| US20140261488A1 (en) * | 2013-03-15 | 2014-09-18 | Altria Client Services Inc. | Electronic smoking article |
| CA2974324A1 (fr) | 2015-01-28 | 2016-08-04 | Zita S. Netzel | Procedes et systemes d'administration de medicament |
| HUE064899T2 (hu) | 2015-03-11 | 2024-04-28 | Alexza Pharmaceuticals Inc | Antisztatikus anyagok használata a légcsatornában a termális aeroszol kondenzációs folyamat létrehozására |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| US10433580B2 (en) | 2016-03-03 | 2019-10-08 | Altria Client Services Llc | Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge |
| US10455863B2 (en) | 2016-03-03 | 2019-10-29 | Altria Client Services Llc | Cartridge for electronic vaping device |
| US10368580B2 (en) | 2016-03-08 | 2019-08-06 | Altria Client Services Llc | Combined cartridge for electronic vaping device |
| US10368581B2 (en) | 2016-03-11 | 2019-08-06 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
| US20170258140A1 (en) | 2016-03-11 | 2017-09-14 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
| US10357060B2 (en) | 2016-03-11 | 2019-07-23 | Altria Client Services Llc | E-vaping device cartridge holder |
| CA3049529A1 (fr) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Dispositifs et methodes d'administration transdermique de medicament |
| GB2604314A (en) | 2017-09-22 | 2022-09-07 | Nerudia Ltd | Device, system and method |
| WO2019162373A1 (fr) * | 2018-02-26 | 2019-08-29 | Nerudia Limited | Dispositif, système et procédé |
| KR102852740B1 (ko) | 2018-02-02 | 2025-08-29 | 알렉스자 파마스티칼즈, 인크. | 전기적 응축 에어로졸 디바이스 |
| JP7420797B2 (ja) | 2018-05-29 | 2024-01-23 | モーニングサイド ベンチャー インベストメンツ リミテッド | 薬剤送達の方法及びシステム |
| EP3880175A4 (fr) | 2018-11-16 | 2022-08-17 | Morningside Venture Investments Limited | Système d'administration transdermique de médicaments à régulation thermique |
| LU101510B1 (en) * | 2019-12-02 | 2021-06-04 | Herrera Arturo Solis | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of an aerosol and dispensing device |
| BR112023002926A2 (pt) * | 2020-08-26 | 2023-04-25 | Cila Therapeutic Inc | Agentes terapêuticos inaláveis |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284089A (en) * | 1978-10-02 | 1981-08-18 | Ray Jon P | Simulated smoking device |
| US4393884A (en) * | 1981-09-25 | 1983-07-19 | Jacobs Allen W | Demand inhaler for oral administration of tobacco, tobacco-like, or other substances |
| US4474191A (en) * | 1982-09-30 | 1984-10-02 | Steiner Pierre G | Tar-free smoking devices |
| DE3241437A1 (de) * | 1982-11-10 | 1984-05-10 | Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt | Mittel zum zwecke der raucherentwoehnung und/oder fuer nebenwirkungsfreien nikotingenuss bei suchtrauchern |
| US4813437A (en) * | 1984-01-09 | 1989-03-21 | Ray J Philip | Nicotine dispensing device and method for the manufacture thereof |
| US4800903A (en) * | 1985-05-24 | 1989-01-31 | Ray Jon P | Nicotine dispenser with polymeric reservoir of nicotine |
| US4715387A (en) * | 1985-08-23 | 1987-12-29 | The Regents Of The Univ. Of California | Aerosol for use in the reduction of tobacco smoking |
| US4793366A (en) * | 1985-11-12 | 1988-12-27 | Hill Ira D | Nicotine dispensing device and methods of making the same |
| US4917120A (en) * | 1986-05-21 | 1990-04-17 | Advanced Tobacco Products, Inc. | Nicotine impact modification |
| GB8614805D0 (en) * | 1986-06-18 | 1986-07-23 | British American Tobacco Co | Aerosol device |
| US4735217A (en) * | 1986-08-21 | 1988-04-05 | The Procter & Gamble Company | Dosing device to provide vaporized medicament to the lungs as a fine aerosol |
| US4765348A (en) * | 1986-12-12 | 1988-08-23 | Brown & Williamson Tobacco Corporation | Non-combustible simulated cigarette device |
| US5834011A (en) * | 1988-02-19 | 1998-11-10 | The Regents Of The University Of California | Method for aiding in the reduction of incidence of tobacco smoking |
| US5824334A (en) * | 1989-09-05 | 1998-10-20 | University Of Utah Research Foundation | Tobacco substitute |
| US5167242A (en) * | 1990-06-08 | 1992-12-01 | Kabi Pharmacia Aktiebolaq | Nicotine-impermeable container and method of fabricating the same |
| DK0557129T3 (da) * | 1992-02-20 | 1997-04-14 | Wielligh Johannes Louw Kot Von | Produkt til at hjælpe rygere med at holde op med at ryge |
| US6024097A (en) * | 1992-02-20 | 2000-02-15 | J Mom Trust | Product for assisting a smoker in giving up the habit |
| US5441060A (en) * | 1993-02-08 | 1995-08-15 | Duke University | Dry powder delivery system |
| GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
| US5497763A (en) * | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| DK0706352T3 (da) * | 1993-06-29 | 2002-07-15 | Ponwell Entpr Ltd | Dispenser |
| US5362496A (en) * | 1993-08-04 | 1994-11-08 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| SE9303574D0 (sv) * | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method the manufacturing thereof |
| US5810018A (en) * | 1994-12-29 | 1998-09-22 | Monte; Woodrow C. | Method, composition and apparatus for reducing the incidence of cigarette smoking |
| US5906202A (en) * | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
| US6196218B1 (en) * | 1999-02-24 | 2001-03-06 | Ponwell Enterprises Ltd | Piezo inhaler |
-
2000
- 2000-07-12 CA CA2378913A patent/CA2378913C/fr not_active Expired - Fee Related
- 2000-07-12 AU AU59312/00A patent/AU777326B2/en not_active Ceased
- 2000-07-12 JP JP2001510544A patent/JP4999245B2/ja not_active Expired - Fee Related
- 2000-07-12 EP EP00945354A patent/EP1218048A4/fr not_active Withdrawn
- 2000-07-12 WO PCT/US2000/019034 patent/WO2001005459A1/fr not_active Ceased
-
2002
- 2002-06-17 US US10/174,000 patent/US20020179102A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1218048A4 (fr) | 2009-08-26 |
| US20020179102A1 (en) | 2002-12-05 |
| WO2001005459A1 (fr) | 2001-01-25 |
| AU777326B2 (en) | 2004-10-14 |
| CA2378913C (fr) | 2010-02-23 |
| AU5931200A (en) | 2001-02-05 |
| EP1218048A1 (fr) | 2002-07-03 |
| CA2378913A1 (fr) | 2001-01-25 |
| JP2003504165A (ja) | 2003-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4999245B2 (ja) | 禁煙を達成するためのシステム | |
| US6799576B2 (en) | System for effecting smoking cessation | |
| US8381739B2 (en) | Systems and methods for effecting cessation of tobacco use | |
| US20140261474A1 (en) | Methods for inhalation of smoke-free nicotine | |
| EP1409049B9 (fr) | Dispositif d'administration d'une substance | |
| EP2086527A2 (fr) | Systèmes destinés à mettre fin à l'usage du tabac | |
| US6102036A (en) | Breath activated inhaler | |
| US20090004249A1 (en) | Dual release nicotine formulations, and systems and methods for their use | |
| US20080138399A1 (en) | Dual release nicotine formulations, and systems and methods for their use | |
| RU2283111C2 (ru) | Забуференная жидкая никотиновая композиция для легочного введения | |
| US7767698B2 (en) | Formulation and use thereof | |
| CA2146954C (fr) | Inhalateur active par la respiration | |
| US20080138294A1 (en) | Systems and methods for effecting cessation of tobacco use | |
| US20110182831A1 (en) | Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use | |
| CN101583354A (zh) | 用于终止烟草使用的系统 | |
| WO2003077846A2 (fr) | Nouvelle methode therapeutique d'administration de medicament permettant d'eviter les effets d'irritation sur les membranes d'un utilisateur | |
| WO1995011678A1 (fr) | Utilisation de substituts de nicotine pour le traitement du sevrage a la nicotine | |
| EP4398964A1 (fr) | Dispositifs et compositions d'administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100326 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100913 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110113 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110317 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120412 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120515 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150525 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |